NEW YORK, Oct. 06, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) resulting from allegations that Brainstorm Cell may have issued materially misleading business information to the investing public.
SO WHAT: If you purchased Brainstorm Cell securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.
WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=19375 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.
WHAT IS THIS ABOUT: On September 27, 2023, the U.S. Food and Drug Administration ("FDA") issued a briefing document rejecting Brainstorm Cell's experimental ALS drug. Brainstorm Cell submitted a biologics license application ("BLA") request in August 2022 and received a ...